An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. - Wikidata - wikimedia - TriplyDB

An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.

An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.

http://www.wikidata.org/entity/Q34682291

about

Lipo191 Lipo203 Lipo224 Lipo246 Lipo256 Lipo276 Lipo314 Lipo355 Lipo502 Lipo514 Lipo573 Lipo585 Lipo601 Lipo624 Lipo651 Lipo675 Lipo723 Lipo815 Lipo863 Lipo956

P1343

Notch activation drives adipocyte dedifferentiation and tumorigenic transformation in mice Axl as a mediator of cellular growth and survival Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma.Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma.Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival.Advances in the targeted therapy of liposarcoma.Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas.The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma Advances in sarcoma genomics and new therapeutic targets.Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma.Characterization of liposarcoma cell lines for preclinical and biological studies.Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.Hypothesis: The Intratumoral Immune Response against a Cancer Progenitor Cell Impacts the Development of Well-Differentiated versus Dedifferentiated Disease in Liposarcoma G protein pathway suppressor 2 (GPS2) acts as a tumor suppressor in liposarcoma.Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma.Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results Liposarcoma: Multimodality Management and Future Targeted Therapies.Liposarcoma: molecular targets and therapeutic implications.Peritoneal sarcomatosis: site of origin for the establishment of an in vitro and in vivo cell line model to study therapeutic resistance in dedifferentiated liposarcoma.Recent translational research into targeted therapy for liposarcoma.MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling.High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma.Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma.Heterogeneity and immunophenotypic plasticity of malignant cells in human liposarcomas.H3K9me3-mediated repression of KLF6: Discovering a novel tumor suppressor in liposarcoma using a systematic epigenomic approach.Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.Can HMGI-C be used as an aid with MDM2 and CDK4 to differentiate liposarcoma subtypes from their mimics?Follicle-stimulating hormone receptor expression in soft tissue sarcomas.Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma.Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression.miR-133a function in the pathogenesis of dedifferentiated liposarcoma.

P2860

Q54902550-6C8767AF-6CC8-4868-8DD8-7A027008EEC0 Q54902551-87E016E7-A125-4E4C-A223-C5D114FAAC35 Q54902552-4371E9C0-FACC-47CF-B2B8-8EB1A164CE0C Q54902553-29BF1955-DB8F-4FBA-93D6-45990F304D15 Q54902554-14BD9100-2D07-455C-A82D-550102A9F462 Q54902555-B2D78175-0B2A-43DA-A442-D636A13CAFDE Q54902557-FD5B8D99-F730-4DE1-8E25-96B56F48ADCB Q54902558-F8031F61-C46A-4AD8-BF88-950AC7AF6418 Q54902559-A28F7D1A-5E03-45BB-9B20-D4D3684116C5 Q54902560-D46A1EBB-E5C0-4DC4-A999-CAC7A523D697 Q54902562-3CA4CE19-092C-4DE6-A69A-B14851F702C5 Q54902563-ECF06DEA-2002-4EC3-B0AB-08C57E4D358A Q54902564-E15B130D-C5C1-4CE5-9C80-F50FFCECE5EC Q54902565-56CE56C7-8BFD-43B5-B98D-CB5CD158E532 Q54902566-3B567F34-EDDA-4A49-A458-0C9BF84CBDB5 Q54902567-C41F848B-FBCD-4844-86DE-22E90188B6B0 Q54902568-0AB22C57-9829-4611-AC06-F8A01E45A6A7 Q54902569-3798C67D-1627-4F91-9217-DD4F3D941772 Q54902570-2C5C90B7-D05D-46C0-9FAA-59B0EF4B7886 Q54902571-1B59F26A-9A9A-4269-8788-BC74A137ACA6

P1343

Q28389770-4552B78D-3B15-4A66-8565-46656A98B094 Q34619118-71A00EEA-0E0A-4F16-9E07-BCCADC356365 Q34619226-8E488FE5-CB50-4E93-91ED-6C1AA998AB98 Q34629045-AFF0F439-4D2D-4BD0-A88D-0C204C0A8FDB Q34633368-A431D911-DA94-484C-A154-B5B7314FE4B4 Q34952133-A4633B2C-E8B2-4E08-BB0D-253436A5EB6E Q35818801-92F5064D-7CEB-4A2A-B920-ECA530FD135D Q35843071-8796B319-406D-4321-A656-A4C70B6E7FFE Q35904618-C987A2F4-4E5E-45D5-A0F9-42405D11E922 Q35993346-55DD441B-F413-491F-9BF3-41F8EB5E9DCF Q36040449-77C5E254-97DC-4F7E-B168-05EA7FBE46CA Q36111589-ACECBC50-061A-40F0-BB25-32AC3B0638BD Q36438319-5C56E4CD-D018-4AD2-BF24-67485F458861 Q36548712-FC2EE487-6E06-4DF9-8983-D476205A4B72 Q36642763-02B7DFD9-FE02-41F9-B7C5-7BDB52A74661 Q36989914-5E96F8F4-6240-496C-9424-F79347948FCC Q37396062-555394D8-E35A-4FDD-9476-59B26D5DDC5E Q37706527-416B48BC-BB79-478C-920C-B915880CCED2 Q38161734-409589E1-7509-45B5-AE34-ACAF5F97189A Q38824691-D3D1F483-708A-4A7B-993F-4771A5552689 Q38833050-2CA66972-1BD0-4D02-BC1C-1EEF376E1F35 Q38835065-4CFF6236-6F99-4E96-9D03-6B0B9864E05D Q39265801-4F8D98F5-CDD8-4ED7-978A-F5499C431A01 Q39393414-EC817788-E2A6-4F64-9D05-98F57506E4E2 Q39724344-4C59EA55-9BD9-4BAC-8F38-F3932F9B18FF Q41370229-2CF5A825-23BF-4E6D-98F7-A9124A6CFE26 Q42544953-155194E9-FAC2-4251-8657-A477616348FF Q42705253-641355DD-ED6C-4FC1-BC4C-956D9CC0F42C Q43991475-6DCE09E3-3319-4A7D-962E-7E0C269073A9 Q44650759-0BC7D72B-D956-42E0-B77E-1DE9A8432B57 Q46247480-28FFE7AB-AABA-4382-BB65-CDF5857749D1 Q47148669-55947F91-6253-4B8A-9BD6-0E0BF149C6BD Q52766495-454653D5-25E9-4400-B48C-D555CA4FD197 Q55443461-E5672865-FE27-4FCA-854E-906FB16620F8

P2860

An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.

http://www.wikidata.org/entity/Q34682291

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

An experimental model for the ...... ble tyrosine kinase receptors.

@ast

An experimental model for the ...... ble tyrosine kinase receptors.

@en

An experimental model for the ...... ble tyrosine kinase receptors.

@nl

type

label

An experimental model for the ...... ble tyrosine kinase receptors.

@ast

An experimental model for the ...... ble tyrosine kinase receptors.

@en

An experimental model for the ...... ble tyrosine kinase receptors.

@nl

prefLabel

An experimental model for the ...... ble tyrosine kinase receptors.

@ast

An experimental model for the ...... ble tyrosine kinase receptors.

@en

An experimental model for the ...... ble tyrosine kinase receptors.

@nl

P1433

Q34682291-296F459A-01AA-4CD1-A1E6-E023E84FA901

P1476

Q34682291-AA150508-2679-4B78-A271-9CE2AB27FCBA

P2093

Q34682291-2C011E63-D160-4260-8A72-7266DF8E9652

Q34682291-36CD658B-4461-4480-A0AB-0C2455D45016

Q34682291-3AF14A89-7914-4309-882E-8D28F2C4C541

Q34682291-43F47ACF-2B6A-4069-8705-AA0D67CBE5D6

Q34682291-4928C05E-43E6-484C-AD7A-471D84638E8F

Q34682291-68056EF2-D8D6-4AFF-B200-F361502FFDFE

Q34682291-79D64E77-5AE2-4D25-808A-32769CE655A3

Q34682291-AF5F3278-ACDA-44E7-944A-32145D276015

Q34682291-B7B71D6C-E408-4C67-9A1F-60226577C672

Q34682291-EA66D70D-A43F-4124-84F1-266895214A44

P2860

Q34682291-020EFE61-90D8-4A43-80A9-FE31590B160B

Q34682291-02F364FC-13F5-4B03-A6B5-59D392E283F6

Q34682291-0300661F-CCE9-44A6-8FC9-4DE0CCF61479

Q34682291-09AA55AB-C060-4439-969D-9F9B8536F80B

Q34682291-0F0F2207-D6E1-466D-BC1C-4B8CE33B23CF

Q34682291-335B8A6F-BE83-4A1F-A42A-E8A26E5E299A

Q34682291-3628E6B3-C01C-4336-BB2F-C91E2A03CA65

Q34682291-398264A4-F986-4C0E-85C8-60F308120BB3

Q34682291-523136CA-38EB-47AD-97B3-3C58A000A69B

Q34682291-53111096-7FA6-4C87-88F3-69A5ABD58C03

P2888

Q34682291-B6615C3B-D6A5-4B60-BD9E-BCBAEA8BCDFD

P304

Q34682291-6D72213E-5DAA-4925-85AE-1E0263564F9D

P31

Q34682291-43CF9F28-F3B3-45DB-8DDE-8D517E00D33E

P356

Q34682291-0559AFC4-96F7-4611-8BE2-3434B2A349E4

P433

Q34682291-6008CA88-7BCA-4D90-ACD4-198DA75F82D2

P4510

Q34682291-0865B8A5-95BE-4B2F-A766-D48B45CF6B9C

Q34682291-09A4B484-222D-4B3E-AB63-CDB763BD7684

Q34682291-13688ADD-BB33-4D06-A0B0-7C3E7128E83E

Q34682291-30C39572-AD35-4C99-9C1E-D98AF2A87B3F

Q34682291-31644D50-A744-4B01-8EAF-0D27706227CC

Q34682291-3E6FBFB9-B213-4819-8668-A6114776FDA4

Q34682291-4617C6DC-EBA8-4DEF-80DE-07C5F7D33580

Q34682291-48A19A2D-A54B-404D-AFF8-41315FCDB7D1

Q34682291-730B3D3F-8F8C-4FAF-9C26-395410AFE2D4

Q34682291-79CF9606-769A-40C8-8B07-474668605424

P478

Q34682291-F04785A1-0661-42BD-B80B-4D22A325D2D6

P50

Q34682291-55252AF1-6945-4485-89A7-635E79CF19BD

Q34682291-9B09294F-C583-4F51-917F-37A57BEE4EF4

P577

Q34682291-C6A62276-98AA-4167-8AA8-70406E327225

P5875

Q34682291-3AA15092-AA77-4308-9F78-D3822416016B

P6179

Q34682291-1D3CAC07-D60D-4C68-B4F2-9146183BD9EE

P698

Q34682291-37C17E1F-227C-4C02-AD8B-5376001F9BF4

P921

Q34682291-AB166C45-7D5B-4E73-B59F-F1F19DD61594

P932

Q34682291-DEC5AD85-E7A1-4988-8B6A-C50C7C293BB9

P356

LABINVEST.2010.185

P1433

Laboratory Investigation

P1476

An experimental model for the ...... ble tyrosine kinase receptors.

@en

P2093

Andre M Oliveira

http://www.w3.org/2001/XMLSchema#string

Delores H López-Terrada

http://www.w3.org/2001/XMLSchema#string

Dina Lev

http://www.w3.org/2001/XMLSchema#string

Jeffery Liu

http://www.w3.org/2001/XMLSchema#string

Kari Brewer

http://www.w3.org/2001/XMLSchema#string

Pingyu Zhang

http://www.w3.org/2001/XMLSchema#string

Roman Belousov

http://www.w3.org/2001/XMLSchema#string

Svetlana Bolshakov

http://www.w3.org/2001/XMLSchema#string

Theresa Nguyen

http://www.w3.org/2001/XMLSchema#string

Tingsheng Peng

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

MDM2--master regulator of the p53 tumor suppressor protein

JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas

Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies

Other targetable sarcomas.

Diagnosis and management of lipomatous tumors.

Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors.

A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas.

Cyclin D-dependent kinases, INK4 inhibitors and cancer.

Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours.

P2888

labinvest.2010.185

P304

392-403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LABINVEST.2010.185

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P4510

P478

91

http://www.w3.org/2001/XMLSchema#string

P50

Alexander J. Lazar

P577

2010-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47718245

http://www.w3.org/2001/XMLSchema#string

P6179

1008419137

http://www.w3.org/2001/XMLSchema#string

P698

21060307

http://www.w3.org/2001/XMLSchema#string

P921

P932

3058694

http://www.w3.org/2001/XMLSchema#string